Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern

被引:80
作者
Nugiel, DA [1 ]
Vidwans, A [1 ]
Etzkorn, AM [1 ]
Rossi, KA [1 ]
Benfield, PA [1 ]
Burton, CR [1 ]
Cox, S [1 ]
Doleniak, D [1 ]
Seitz, SP [1 ]
机构
[1] Bristol Myers Squibb Co, Wilmington, DE 19880 USA
关键词
D O I
10.1021/jm020171+
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We disclose a novel series of indenopyrazole-based cyclin-dependent kinase (CDK) inhibitors. Kinetic experiments confirmed our initial molecular modeling studies that the compounds are competitive with respect to adenosine 5'-triphosphate (ATP) and bind in the kinase ATP pocket. A unique combination of active pharmacophores led us to a series of semicarbazide-based. inhibitors that are highly potent against CDK2 and CDK4 while maintaining selectivity against other relevant serine/threonine kinases. These compounds were active against a transformed human colon cancer cell line (HCT116) while maintaining an acceptable margin of activity against a normal fibroblast cell line. The compounds were found to be highly protein bound in our cell-based assay with the exception of 11k, which maintained a reasonable level of activity in the presence of human plasma proteins.
引用
收藏
页码:5224 / 5232
页数:9
相关论文
共 35 条
  • [1] Akinaga S, 2000, ANTI-CANCER DRUG DES, V15, P43
  • [2] Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
    Arris, CE
    Boyle, FT
    Calvert, AH
    Curtin, NJ
    Endicott, JA
    Garman, EF
    Gibson, AE
    Golding, BT
    Grant, S
    Griffin, RJ
    Jewsbury, P
    Johnson, LN
    Lawrie, AM
    Newell, DR
    Noble, MEM
    Sausville, EA
    Schultz, R
    Yu, W
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) : 2797 - 2804
  • [3] Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases
    Barvian, M
    Boschelli, DH
    Cossrow, J
    Dobrusin, E
    Fattaey, A
    Fritsch, A
    Fry, D
    Harvey, P
    Keller, P
    Garrett, M
    La, F
    Leopold, W
    McNamara, D
    Quin, M
    Trumpp-Kallmeyer, S
    Toogood, P
    Wu, ZP
    Zhang, EL
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (24) : 4606 - 4616
  • [4] Carlson BA, 1996, CANCER RES, V56, P2973
  • [5] Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
    deAzevedo, WF
    MuellerDieckmann, HJ
    SchulzeGahmen, U
    Worland, PJ
    Sausville, E
    Kim, SH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (07) : 2735 - 2740
  • [6] CRYSTAL-STRUCTURE OF CYCLIN-DEPENDENT KINASE-2
    DEBONDT, HL
    ROSENBLATT, J
    JANCARIK, J
    JONES, HD
    MORGAN, DO
    KIM, SH
    [J]. NATURE, 1993, 363 (6430) : 595 - 602
  • [7] Cell cycle control and cancer
    Draetta, G
    Pagano, M
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 31, 1996, 31 : 241 - 248
  • [8] Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717
    Dreyer, MK
    Borcherding, DR
    Dumont, JA
    Peet, NP
    Tsay, JT
    Wright, PS
    Bitonti, AJ
    Shen, J
    Kim, SH
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (04) : 524 - 530
  • [9] 3D-QSAR CoMFA on cyclin-dependent kinase inhibitors
    Ducrot, P
    Legraverend, M
    Grierson, DS
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (22) : 4098 - 4108
  • [10] Fischer P M, 2001, Curr Opin Drug Discov Devel, V4, P623